about
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.Mantle cell lymphoma - Current standards of care and future directions.Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.Novel Immunotherapies for T Cell Lymphoma and LeukemiaA Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana LinfomiBendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyKMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
P50
Q35759705-066A85DB-2FF8-434D-BC31-2DF5E3901293Q36596874-573B48F4-51E7-444B-84DE-26F20126226EQ38666572-58F70646-5771-441E-825C-2B809881121FQ39628753-C30A7FA5-E91C-42FD-920A-CE2E03AA7325Q40134863-C106D766-D330-4EB4-88DA-8C0DCD3F3011Q42120007-DF49DB89-7473-4E5B-A0B2-69291567C13BQ48335780-73AAC5CA-A17C-4203-8D03-73AA59AA5D0AQ48371948-519E3B57-AC8E-4ED4-8719-28410A596711Q49870129-26C5D6CB-ED8C-4739-BD15-3E0AAB00CE25Q52863507-EC544D97-ECCA-4A97-A91A-088AC51375E4Q52912068-1024117A-5217-4630-8A1A-A790EBFE1159Q52969991-BDD291EA-FFB4-4F44-A10C-5551C6536BB8Q57468335-70EABFBC-1604-4835-8248-E58F868CC10EQ88951248-DC517CC7-CEF5-4206-9CCD-F333295E8804Q89274814-7F1D01C7-1650-421A-878B-ED84D1691777Q90182576-C6EE820F-CCB2-4129-9814-FE25F56FC5CC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paola Ghione
@ast
Paola Ghione
@en
Paola Ghione
@es
Paola Ghione
@nl
type
label
Paola Ghione
@ast
Paola Ghione
@en
Paola Ghione
@es
Paola Ghione
@nl
prefLabel
Paola Ghione
@ast
Paola Ghione
@en
Paola Ghione
@es
Paola Ghione
@nl
P106
P1153
54683936800
P21
P31
P496
0000-0001-6986-7954